NCT01670084: Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia |
|
|
| Withdrawn | 2 | 0 | US | nilotinib, AMN 107, Tasigna, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, doxorubicin hydrochloride, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, methotrexate, amethopterin, Folex, methylaminopterin, Mexate, MTX, cytarabine, ARA-C, arabinofuranosylcytosine, arabinosylcytosine, Cytosar-U, cytosine arabinoside, prednisone, DeCortin, Deltra, mesna, mercaptoethane sulfonate, Mesnex, MSA, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, leucovorin calcium, CF, CFR, LV | Mayo Clinic | B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia | 09/15 | 09/17 | | |
